Lung-MAP: A beacon of hope for lung cancer patients : vimars

The unique public-private partnership that for almost a decade has undergirded the first National Cancer Institute (NCI)-sponsored precision medicine clinical trial in lung cancer can serve as a model for future clinical research that is more rapid, innovative, and inclusive.

Related Keywords

Oregon , United States , Charlesd Blanke , Roys Herbst , Ellenv Sigal , , National Clinical Trials Network , Genentech , Friends Of Cancer Research , Bristol Myers Squibb Company , Astrazeneca , National Institutes Of Health , Cancer Research Network , Amgen , Science University , Yale School Of Medicine , Clinical Cancer Research , Yale Cancer Center , Pfizer , Foundation For The National Institutes Of Health , Swog Cancer Research Network , Foundation Medicine , Oregon Health , National Cancer Institute , Lung Cancer Master Protocol , Clinical Cancer , Smilow Cancer Hospital , Ensign Professor , Yale School , National Institutes , Research Network , Cancer Research , Clinical Trials Network , Patients Enrolled , Lung Cancer Master , Trial Diversity , Arc Toward , Research , Ancer , Ell , Clinical Trial , Rugs , Enetic , Enomic , Ospital , Lung Cancer , Edicine , Non Small Cell Lung Cancer , Ncology , Precision Medicine , Small Cell Lung Cancer , Umor ,